Morgan Stanley raised the firm’s price target on Insulet (PODD) to $370 from $355 and keeps an Overweight rating on the shares. Insulet pressed its advantage in Q2, taking outsized share of MDI conversions while also accelerating competitive conversions, according to the firm. While the pump market can still clearly accommodate multiple players and form factor offerings, prescribers and patients are choosing Omnipod increasingly often, and PODD is uniquely positioned amidst reimbursement trends favoring pay-as-you-go economics, Morgan Stanley told investors in a research note. The firm added that Insulet’s reacceleration in International sales shaping up over the past several quarters is perhaps even more “remarkable” and remains an “underappreciated” part of the story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $375 from $360 at Jefferies
- Insulet’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Early notable gainers among liquid option names on August 7th
- Morning Movers: Apple adds to yesterday’s gains, Trump calls out Intel CEO
- Insulet up 13% at $313.45 after Q2 earnings beat and guidance raise